The IND clearance is for the autoimmune disease indications non-renal systemic lupus erythematosus and lupus nephritis. Credit: Sebastian Kaulitzki/Shutterstock. IASO Biotherapeutics has secured US Food
The deal expansion aims to ensure a future supply of the therapeutic radiopharmaceutical for clinical trial sites in the UK, EU and US. Credit: IM
AHB-137 is a new therapeutic option for patients with chronic hepatitis B. Credit: Peakstock/Shutterstock. AusperBio Therapeutics and Ausper Biopharma have gained breakthrough therapy designation (BTD)
ODAIA, a life sciences predictive analytics and commercial insights provider, has secured an investment of $25m in its Series B funding round. The round was